SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose, COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use. We'll issue specific code descriptors in the future. New York State Department of Health. r ``8*EX If informed consent or reconsent (ie., asked to sign a revised consent or another informed consent) is obtained from research subjects after the compliance date, the covered entity must obtain individual authorization as required at 45 CFR 164.508 for the use or disclosure of protected health information once the consent obtained before the compliance date is no longer valid for the research. Who is a "Qualified Person" for Purposes of Access to a Patient's B. The Privacy Rule requires that an Authorization contain either an expiration date or an expiration event that relates to the individual or the purpose of the use or disclosure. Saving Lives, Protecting People, COVID-19 Emergency Use Authorization Recipient and Caregiver Fact Sheets, https://www.cdc.gov/vaccines/covid-19/eua/moderna-over-5-months.html, https://www.cdc.gov/vaccines/covid-19/eua/moderna-over-5-months.pdf, https://www.cdc.gov/vaccines/covid-19/eua/pfizer-over-5-months.html, https://www.cdc.gov/vaccines/covid-19/eua/pfizer-over-5-months.pdf, https://www.cdc.gov/vaccines/covid-19/eua/janssen.html, https://www.cdc.gov/vaccines/covid-19/eua/janssen.pdf, https://www.cdc.gov/vaccines/covid-19/eua/novavax.html, https://www.cdc.gov/vaccines/covid-19/eua/novavax.pdf, National Center for Immunization and Respiratory Diseases, Core Data Elements For IIS Functional Standards v4.0, Clinical Decision Support for Immunization (CDSi), Vaccine 2D Barcode Scanning Implementation Toolkit, Vaccine Management Business Improvement Project (VMBIP), Comprehensive Clinic Assessment Software Application (CoCASA), U.S. Department of Health & Human Services, 510^10 viral particles/0.5 mL for adult 18+, SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL, COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 51010 viral particles/0.5 mL dosage, for intramuscular use.
Marco Hajikypri Net Worth, Articles H